[Skip to content]

EPDA - European Parkinsons Disease Association
Friday 10 September 2010
.

References

  1. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging. 2004; 21(11):687-709.

  2. Hagell P, Odin P. Apomorphine in the treatment of Parkinson’s disease. J Neurosci Nurs. 2001 Feb;33(1):21-34, 37-8.

  3. Olanow CW, Obeso JA, Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol. 2006 Jul;2(7):382-92

  4. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother. 2006 Oct;6(10):1403-11.

  5. Eggert K., Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P. (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson´s disease: Practical aspects and outcome of motor and non-motor complications. Clin. Neuropharmacol 2008 31:151-66.

  6. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord. 2007 Jun 15;22(8):1145-9.

  7. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, Pacchetti C, Zibetti M, Natuzzi F, Lopiano L, Nappi G, Pezzoli G. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Dis. 2008;5(3-4):244-6.

  8. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol. 2008 Mar-Apr; 31(2):63-73.

  9. Volkmann J. Update on surgery for Parkinson’s disease. Curr Opin Neurol. 2007 Aug;20(4):465-9.

  10. De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, Natuzzi F, Morgante L, Mariani CB, Sganzerla E, Pezzoli G, Antonini A. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):450-3.

  11. Alegret M, Valldeoriola F, Martí M, Pilleri M, Junqué C, Rumià J, Tolosa E. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord. 2004 Dec; 19(12):1463-9.